Efficiency of dimephosphone in sinus node weakness syndrome in children

The comparative study of efficiency of dimephosphone (50—100 mg/kg/day intravenously in dropper) cytochrome c (0,5 mg/kg/day intravenously in dropper) and the standard treatment scheme in 121 children with sinus node weakness syndrome is carried out. It is shown that monotherapy with dimephosphone made it possible to reach the therapeutic effect in children with the I clinicoelectrocardiographic continuation of the disease. In the II and III types the addition of dimephosphone to the standard scheme increased its efficiency by 27—30%. The validity of continuation the neurometablic therapy with sinus node weakness syndrome during half a year and pe forming three courses of treatment with the drug at the interval of three months is shown.